about
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitusSodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for development of type 2 diabetes mellitusInteractions between kidney disease and diabetes: dangerous liaisonsRegulatory roles of nitric oxide and angiotensin II on renal tubular transportSodium-retaining effect of insulin in diabetesSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinUric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese populationTissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in ratsOptimal Pharmacologic Treatment Strategies in Obesity and Type 2 DiabetesLive imaging of GLUT2 glucose-dependent trafficking and its inhibition in polarized epithelial cysts.Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Metabolic syndrome, serum uric acid and renal risk in patients with T2D.Mobilization and removing of cadmium from kidney by GMDTC utilizing renal glucose reabsorption pathwayCommon variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations.The effects of acute renal denervation on kidney perfusion and metabolism in experimental septic shockEmpagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Fasting plasma glucose and serum uric acid levels in a general Chinese population with normal glucose tolerance: A U-shaped curve.Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesAldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats.Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsAngiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvationSodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the potInhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibitionSGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.The role of Klotho in energy metabolism.Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialA Renal Olfactory Receptor Aids in Kidney Glucose Handling.Characteristics and Impact Factors of Renal Threshold for Glucose Excretion in Patients with Type 2 Diabetes Mellitus.Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy?Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
P2860
Q24185874-1CD01675-57AC-4523-9CE8-94334E501A5EQ24186087-E411EC36-C679-4DA0-8AC2-9DAF4BA30420Q26740630-736DED64-E89E-40CF-BA0E-E9DA1EB65653Q27012509-D65E260B-DE9C-4622-B22C-7F60078BF003Q27015001-65674A52-2BF5-4AA3-B1E9-2D99AD758356Q28072765-4BF27A55-8DFF-4CD2-B466-88DAE57EE175Q28079134-AA7F2243-D27A-472E-838D-A2BB1AF444C6Q28250844-FAB8C83A-B08F-457F-8D91-37BEE59761CAQ28547672-6C5B17EC-6F7E-4FF1-BE8C-A2FB7B490E84Q28572929-CD7440BE-1115-4D22-B811-FBBA9D831313Q30377441-33F87204-F781-430B-B3B7-D8A1B412064DQ30585623-D5727A9B-4703-4152-BB3A-8E0AF3CD9BAEQ30833760-9FC5052E-9FC7-429F-B29B-B15325FDCD15Q33579624-91B12FC6-89A4-4976-84EF-BC207E25C714Q33594514-BBAFE0EB-1B58-493A-BFBD-BBE10E41B493Q33638177-AD63BF7F-02B6-49F6-862F-77F85EFA4690Q33749793-D434BAFF-D04E-4E83-928C-4A8BB0D0376DQ33837017-6FC288F8-36F6-4A76-AC7C-D047466970FBQ33848499-FC70A29C-5B1D-455B-92B0-F7B93946DDB0Q33857698-40FC8F6F-1E6A-4236-8E47-A7F74DC61DF7Q34161881-86C64BDA-530B-4C35-B240-771FA8ED5EE6Q34198692-C2435AB3-9782-40BB-B853-4E1D0F25F46EQ34326639-A79804EC-DC6F-44C0-A49E-3B61E6A5695AQ34579919-A7ED67AF-40A5-41EE-B806-763D63B43E6EQ34973750-96F76EC8-BCB1-4490-9C9C-3DAD451B128EQ35105160-E00F229D-BFFF-4B44-BEDC-87575CB7DDF6Q35192356-B778756B-D7CF-493A-8443-E5F99A4341F9Q35392355-C876D631-614E-417D-A580-545070533F18Q35749639-9D49B33C-8346-41C6-BB88-9EDEEC393912Q35906490-2B9289B8-5B6A-4D37-8972-301D366A8331Q36232787-FC724B75-FA77-4273-80D9-2A541A8B61C6Q36354599-547B41EF-0BCA-44FA-9A4A-59BC3A97C405Q36828139-31F1E0A2-2610-49B1-BAE3-08D3488CDB49Q36992839-5C26CFF4-DCDC-4EBA-BD0C-3033187E6A34Q37278239-A951E08C-3765-4034-A991-B5C5B86CA8C2Q37339712-47D996AF-BDC0-440A-83F4-89157FD1B3BAQ37677733-AD2A8995-5F2C-4D8C-914D-354803057499Q37686261-A7A5903C-3370-4DD4-88B5-81C188816FD1Q38009886-5E7EB024-B8CA-47B9-9889-9A599AC59605Q38113101-5F6AE05C-E82D-4AD6-90D2-9D840BD0BF02
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glucose handling by the kidney.
@en
Glucose handling by the kidney.
@nl
type
label
Glucose handling by the kidney.
@en
Glucose handling by the kidney.
@nl
prefLabel
Glucose handling by the kidney.
@en
Glucose handling by the kidney.
@nl
P356
P1476
Glucose handling by the kidney.
@en
P2093
Amanda Mather
Carol Pollock
P356
10.1038/KI.2010.509
P577
2011-03-01T00:00:00Z